Evidence map›Paper›PMID 35164882›Full record

ArticleActa neuropathologica communications2022

Proximity proteomics of C9orf72 dipeptide repeat proteins identifies molecular chaperones as modifiers of poly-GA aggregation.

Feilin Liu, Dmytro Morderer, Melissa C Wren, Sara A Vettleson-Trutza, Yanzhe Wang, Benjamin E Rabichow, Michelle R Salemi, Brett S Phinney, Björn Oskarsson, Dennis W Dickson and 1 more

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Brain communications · 2026
    Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. C9orf72-linked arginine-rich dipeptide repeats aggravate pathological phase separation of G3BP1.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. iScience · 2023
    Article
  19. Toxicity ofLife science alliance · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Feilin Liu *Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Dmytro Morderer *Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Melissa C WrenDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Sara A Vettleson-TrutzaDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Yanzhe WangDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Benjamin E RabichowDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Michelle R SalemiProteomics Core, University of California Davis, Davis, CA, USA.
Brett S PhinneyProteomics Core, University of California Davis, Davis, CA, USA.
Björn OskarssonDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Wilfried RossollDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA. rossoll.wilfried@mayo.edu.ORCID 0000-0002-9622-541X
Mayo Clinic in Florida · USUniversity of California, Davis · USFirst Hospital of China Medical University · CNJacksonville College · USSecond Affiliated Hospital of Jilin University · CNWinnMed · US

Funding

Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$33.5M
Project 3: Neuropathology of the multi-proteinopathy of c9FTD/ALS.P01NS084974 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2014 to 2024
$17.6M
High-throughput Screen for Discovery of Ciliary Neurotrophic Factor (CNTF) Receptor Agonists for the Treatment of Amyotrophic Lateral Sclerosis (ALS)R33NS110960 · NINDS · MAYO CLINIC JACKSONVILLE · PI ROSSOLL, WILFRIED · 2020 to 2021
$893k
High-throughput Screen for Discovery of Ciliary Neurotrophic Factor (CNTF) Receptor Agonists for the Treatment of Amyotrophic Lateral Sclerosis (ALS)R61NS110960 · NINDS · MAYO CLINIC JACKSONVILLE · PI ROSSOLL, WILFRIED · 2019 to 2019
$454k
Howard Hughes Medical InstituteNIA NIH HHS NS084974NIA NIH HHS P30 AG062677NINDS NIH HHS P01 NS084974NINDS NIH HHS R33 NS110960NINDS NIH HHS R61 NS110960
6 · The paper itself

Abstract

The most common inherited cause of two genetically and clinico-pathologically overlapping neurodegenerative diseases, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), is the presence of expanded GGGGCC intronic hexanucleotide repeats in the C9orf72 gene. Aside from haploinsufficiency and toxic RNA foci, another non-exclusive disease mechanism is the non-canonical translation of the repeat RNA into five different dipeptide repeat proteins (DPRs), which form neuronal inclusions in affected patient brains. While evidence from cellular and animal models supports a toxic gain-of-function of pathologic poly-GA, poly-GR, and poly-PR aggregates in promoting deposition of TDP-43 pathology and neurodegeneration in affected brain areas, the relative contribution of DPRs to the disease process in c9FTD/ALS patients remains unclear. Here we have used the proximity-dependent biotin identification (BioID) proximity proteomics approach to investigate the formation and collective composition of DPR aggregates using cellular models. While interactomes of arginine rich poly-GR and poly-PR aggregates overlapped and were enriched for nucleolar and ribosomal proteins, poly-GA aggregates demonstrated a distinct association with proteasomal components, molecular chaperones (HSPA1A/HSP70, HSPA8/HSC70, VCP/p97), co-chaperones (BAG3, DNAJA1A) and other factors that regulate protein folding and degradation (SQSTM1/p62, CALR, CHIP/STUB1). Experiments in cellular models of poly-GA pathology show that molecular chaperones and co-chaperones are sequestered to the periphery of dense cytoplasmic aggregates, causing depletion from their typical cellular localization. Their involvement in the pathologic process is confirmed in autopsy brain tissue, where HSPA8, BAG3, VCP, and its adapter protein UBXN6 show a close association with poly-GA aggregates in the frontal cortex, temporal cortex, and hippocampus of c9FTLD and c9ALS cases. The association of heat shock proteins and co-chaperones with poly-GA led us to investigate their potential role in reducing its aggregation. We identified HSP40 co-chaperones of the DNAJB family as potent modifiers that increased the solubility of poly-GA, highlighting a possible novel therapeutic avenue and a central role of molecular chaperones in the pathogenesis of human C9orf72-linked diseases.

Indexed as

Amyotrophic Lateral SclerosisC9orf72 ProteinFrontotemporal DementiaProtein Aggregation, PathologicalRepetitive Sequences, Nucleic AcidDipeptidesHEK293 CellsHumansMolecular ChaperonesProteomicsRNAC9orf72 ProteinC9orf72 protein, humanDipeptidesMolecular ChaperonesRNAC9orf72Heat shock proteinsPoly-GAProximity proteomics

Identifiers

PMID35164882
PMCPMC8842533
OpenAlexW4212805421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.